SEDANA MEDICAL AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.34 SEK | -1.24% |
|
-3.50% | -38.08% |
| Feb. 15 | Transcript : Sedana Medical AB, Q4 2023 Earnings Call, Feb 15, 2024 | |
| Feb. 15 | Sedana Medical AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 181M 16.58M | Sales 2025 * | 243M 22.25M | Capitalization | 1.42B 130M |
|---|---|---|---|---|---|
| Net income 2024 * | -61M -5.59M | Net income 2025 * | -35M -3.21M | EV / Sales 2024 * | 6.75 x |
| Net cash position 2024 * | 203M 18.57M | Net cash position 2025 * | 56.05M 5.13M | EV / Sales 2025 * | 5.63 x |
| P/E ratio 2024 * |
-23.1
x | P/E ratio 2025 * |
-41.5
x | Employees | 79 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 63.5% |
More Fundamentals
* Assessed data
More news
Latest transcript on Sedana Medical AB
More press releases
More news
| 1 day | -1.24% | ||
| 1 week | -3.50% | ||
| Current month | -10.43% | ||
| 1 month | -3.11% | ||
| 3 months | -33.36% | ||
| 6 months | -15.15% | ||
| Current year | -38.08% |
1 week
14.00
15.32
1 month
14.0016.74
Current year
14.0024.50
1 year
14.0034.50
3 years
14.00111.00
5 years
14.00111.00
10 years
5.00111.00
| Managers | Title | Age | Since |
|---|---|---|---|
Johannes Doll
CEO | Chief Executive Officer | 43 | 21-09-30 |
Johan Spetz
DFI | Director of Finance/CFO | - | 22-04-03 |
Peter Fröberg
CTO | Chief Tech/Sci/R&D Officer | 53 | 20-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hilde Furberg
BRD | Director/Board Member | 65 | 21-12-31 |
| Director/Board Member | 49 | 20-05-18 | |
Claus Bjerre
CHM | Chairman | 53 | 21-05-09 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 14.34 | -1.24% | 173,652 |
| 24-04-18 | 14.52 | -0.95% | 67,272 |
| 24-04-17 | 14.66 | -2.14% | 117,817 |
| 24-04-16 | 14.98 | +1.49% | 68,421 |
| 24-04-15 | 14.76 | -0.67% | 65,056 |
Delayed Quote Nasdaq Stockholm, April 19, 2024 at 11:29 am EDT
More quotes
Sedana Medical AB (publ) is a Sweden-based medical technology company. It develops, markets and sales medical devices and conducts drug development for future projects around AnaConDa technology. The AnaConDa technology delivery enables of volatile anaesthetics to invasively ventilated patients. The products portfolio comprises disposable medical devices AnaConDa for administration of volatile anaesthetics, AnaConDa syringes, FlurAbsorb charcoal filters for removing halogenated hydrocarbon anaesthetic gases, different lines and connectors which can be used to connect the FlurAbsorb filter, adaptors, among others. The Companyâs main shareholders are board members, Linc AB and Magiola Consulting AB.
Calendar
2024-04-25
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
14.34
SEK
Average target price
35.5
SEK
Spread / Average Target
+147.56%
EPS Revisions
- Stock Market
- Equities
- SEDANA Stock
